Professor | Georgetown University | United States
Dr. Jill P. Smith is a distinguished Professor of Medicine at Georgetown University, holding dual appointments in the Departments of Medicine and Oncology, with leadership roles at the Lombardi Comprehensive Cancer Center. Her academic journey, from the University of Florida through the University of Missouri to her fellowship in Gastroenterology and Hepatology, has been marked by an enduring dedication to translational science and Cancer therapeutics. Over her illustrious career, Dr. Smith has pioneered landmark studies in Cancer therapeutics, particularly focusing on pancreatic and liver malignancies. Her investigations into cholecystokinin (CCK) receptor signaling, pancreatic tumor biology, and the development of proglumide-based interventions have advanced the understanding of Cancer therapeutics mechanisms at both cellular and systemic levels. She has directed numerous NIH and Department of Defense–funded projects that explore innovative Cancer therapeutics, such as receptor blockade, fibrosis modulation, and nanoparticle-based drug delivery systems. Dr. Smith’s honors include the Harrington Innovator Scholar Award, Bayer Discovery Awards, National Academy of Inventors membership, and Georgetown’s Innovator of the Year recognition—each underscoring her impact on Cancer therapeutics innovation. Her mentorship of generations of researchers and clinicians has fostered growth in translational research and Cancer therapeutics leadership. Her research skills encompass molecular oncology, preclinical modeling, pharmacological design, and clinical trial development in Cancer therapeutics, aligning scientific discovery with patient-centered outcomes. Dr. Smith’s professional excellence and lifelong pursuit of advancing Cancer therapeutics have made her a global authority in gastroenterological oncology. Scopus profile of 3,983 Citations, 109 Documents, 35 h-index.
Profile: Scopus
Featured Publications
1. Nature Communications. (2025). Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33.
2. Cancers. (2025). Mechanistic insights into proglumide’s role in immune cell efficacy and response to immune checkpoint inhibitor therapy in hepatocellular carcinoma.
3. Molecular Cancer Therapeutics. (2025). Target-specific locked nucleic acid gapmer decreases growth and metastases of pancreatic cancer.
4. Livers. (2025). Endogenous alcohol and auto-brewery syndrome complicating liver transplantation: A case report and literature review.
5. Cancer Investigation. (2025). A phase I study of the naturally occurring bioactive, opioid growth factor, in patients with unresectable hepatocellular cancer.